周期蛋白依赖性激酶4/6抑制剂相关肺毒性的文献分析

赵俊; 刘广伟; 林玉燕; 张小蕾; 倪倍倍

doi:10.6039/j.issn.1001-0408.2023.03.19

您当前的位置：

首页 >

文章列表页 >

周期蛋白依赖性激酶4/6抑制剂相关肺毒性的文献分析

药物与临床 | 更新时间：2023-02-22

- 周期蛋白依赖性激酶4/6抑制剂相关肺毒性的文献分析
- Literature analysis of lung toxicity related to cyclin-dependent kinase 4/6 inhibitors
- 中国药房 2023年34卷第3期页码：355-360
- 作者机构：
  
  1.青岛大学附属医院药学部，山东青岛;266003
  2.广州中医药大学深圳医院（福田）药学部，广东深圳　518000
- 作者简介：
  
  副主任药师，硕士。研究方向：临床药理学。电话：0532-82912182。E-mail：Zhaojun@qduhospital.cn
  副主任药师，硕士。研究方向：临床药学。电话：0532-82912182。E-mail：nibeibeiabce@163.com
- 基金信息：
  
  山东省自然科学基金青年项目(ZR2021QH205)
- DOI：10.6039/j.issn.1001-0408.2023.03.19
  中图分类号： R969.3;R979.1
- 纸质出版日期：2023-02-15，
  
  收稿日期：2022-07-05，
  
  修回日期：2023-01-13，
扫描看全文
赵俊,刘广伟,林玉燕等.周期蛋白依赖性激酶4/6抑制剂相关肺毒性的文献分析 ^Δ[J].中国药房,2023,34(03):355-360.

ZHAO Jun,LIU Guangwei,LIN Yuyan,et al.Literature analysis of lung toxicity related to cyclin-dependent kinase 4/6 inhibitors[J].ZHONGGUO YAOFANG,2023,34(03):355-360.
赵俊,刘广伟,林玉燕等.周期蛋白依赖性激酶4/6抑制剂相关肺毒性的文献分析 ^Δ[J].中国药房,2023,34(03):355-360. DOI： 10.6039/j.issn.1001-0408.2023.03.19.

ZHAO Jun,LIU Guangwei,LIN Yuyan,et al.Literature analysis of lung toxicity related to cyclin-dependent kinase 4/6 inhibitors[J].ZHONGGUO YAOFANG,2023,34(03):355-360. DOI： 10.6039/j.issn.1001-0408.2023.03.19.

摘要

目的

为临床合理使用周期蛋白依赖性激酶（CDK）4/6抑制剂提供参考。

方法

计算机检索Web of Science、PubMed、SpringerLink、中国知网、万方数据与维普网等数据库中CDK4/6抑制剂相关肺毒性文献，采用Excel 2013软件进行统计分析。

结果

共纳入12篇符合纳入与排除标准的文献，涉及13例患者，包括美国3例，日本3例，印度2例，以色列、西班牙、法国、澳大利亚、沙特阿拉伯各1例；均为女性患者，年龄在43～89岁之间；所使用的CDK4/6抑制剂类药物包括哌柏西利（8例）、阿贝西利（3例）、瑞博西利（2例）。患者用药后发生肺毒性的时间在1周～15个月不等，多数患者均以呼吸困难、胸闷、气短、干咳等症状为主诉入院，其肺毒性主要表现为间质性肺病、嗜酸性粒细胞性肺炎、纵隔和肺门结节样反应、药物性肺炎、弥漫性肺泡损伤、组织性肺炎等。其治疗时长最短为3周，最长为6个月，治疗措施包括停药、静脉使用抗菌药物、静脉使用全身类固醇、吸氧等；治疗后8例患者好转或康复，5例患者因病情恶化死亡。1例患者再次使用该类药物后又出现肺毒性，须永久停止使用该类药物。

结论

CDK4/6抑制剂相关肺毒性有导致死亡的可能，临床须早期判断、及时停药，并尽早采用给予患者全身类固醇、吸氧等治疗措施。

Abstract

OBJECTIVE

To provide reference for rational use of cyclin-dependent kinase 4/6 （CDK4/6） inhibitors.

METHODS

Retrieved from Web of Science， PubMed， SpringerLink， CNKI， Wanfang Data and VIP database， and so on， the literature about lung toxicity related to CDK4/6 inhibitors were collected and analyzed statistically with Excel 2013 software.

RESULTS

A total of 12 literature which met the inclusion and exclusion criteria were included； 13 patients were involved， among which 3 cases were from the United States， 3 from Japan， 2 from India， and 1 from Israel， Spain， France， Australia and Saudi Arabia respectively； all patients were female， aged between 43-89 years， of whom 8 were treated with palbocicilib， 3 with abemacilib， and 2 with ribociclib. The lung toxicity of patients after medication occurred from 1 week to 15 months； the majority of patients were hospitalized with the symptom such as difficulty breathing， chest tightness， shortness of breath， dry cough， etc. The lung toxicity mainly manifested as interstitial lung disease， eosinophilic pneumonia， mediastinal and pulmonary granulomatous reaction， drug-induced pneumonia， diffuse alveolar damage， organizing pneumonia and so on. The shortest treatment duration was 3 weeks， and the longest was 6 months. The treatment measures included drug withdrawal， intravenous use of antibiotics， intravenous use of systemic steroids， oxygen inhalation， and so on； after treatment， 8 patients improved or recovered， and 5 patients died due to deterioration. One patient developed lung toxicity again after reuse of such drugs and must stop drugs permanently.

CONCLUSIONS

Lung toxicity related to CDK4/6 inhibitors possibly cause mortality. It is necessary to make early judgment， stop the drug in time， and give patients systemic steroids， oxygen inhalation and other treatment measures as soon as possible.

关键词

周期蛋白依赖性激酶4/6抑制剂肺毒性药品不良反应文献分析

Keywords

lung toxicityadverse drug reactionliterature analysis

references

U. S. Food and Drug Administration. Palbocilib（IBRANCE） [EB/OL]. [2022-11-10]. https：//www.fda.gov/drugs/re- sources-informationapproved-drugs/palbociclib-ibrancehttps://www.fda.gov/drugs/re-sources-informationapproved-drugs/palbociclib-ibrance.

U. S. Food and Drug Administration.Ribocilib（Kisqali） [EB/OL]. [2022-11-10].https：//www.fda.gov/drugs/resources-informationapproved-drugs/ribociclib-kisqalihttps://www.fda.gov/drugs/resources-informationapproved-drugs/ribociclib-kisqali.

U.S.Food and Drug Administration.FDA aprroves abemaciclib for HR-positive，HER2-negative breast cancer[EB/OL]. [2022-11-10].https：//www.fda.gov/drugs/resources-information-approved-drugs/fdaapproves-abemaciclib-hr-positive-her2-negative-breast-cancerhttps://www.fda.gov/drugs/resources-information-approved-drugs/fdaapproves-abemaciclib-hr-positive-her2-negative-breast-cancer.

QIN Q，LI X Q，LIANG X M，et al. CDK4/6 inhibitor palbociclib overcomes acquired resistance to third-generation EGFR inhibitor osimertinib in non-small cell lung cancer （NSCLC）[J]. Thorac Cancer，2020，11（9）：2389-2397.

JO H，PARK Y，KIM T，et al. Modulation of SIRT3 expression through CDK4/6 enhances the anti-cancer effect of sorafenib in hepatocellular carcinoma cells[J]. BMC Cancer，2020，20（1）：332.

AHSAN I，MALIK F，JAFRI S. Palbociclib related pnemotoxicity：a rare side effect[J]. Am J Respir Crit Care Med，2017，195：A5546.

KOMODA A，KASHIWAGI S，KAWANO Y，et al. A case of liver abscess during treatment for abemaciclib-induced interstitial lung disease[J]. Gan To Kagaku Ryoho，2022，49（1）：100-102.

MITARAI Y，TSUBATA Y，HYAKUDOMI M，et al. Drug-induced eosinophilic pneumonia as an adverse event of abemaciclib[J]. Cureus，2022，14（1）：e21741.

JAZIEH K A，BUDD G T，DALPIAZ N，et al. Can CDK4/6 inhibitors cause fatal lung injury?[J]. Expert Rev Anticancer Ther，2019，19（11）：917-919.

FELIP E，LLOBERA L，PEREZ-MAÑÁ C，et al. New drugs，old toxicities：pneumonitis related to palbociclib： a case report[J]. Breast Care （Basel），2020，15（5）：548-552.

STOFFAËS L，DUMAZET A，DESLEE G，et al. Sarcoidosis-like reaction during palbociclib treatment for metastatic breast cancer：a case report[J]. Breast J，2020，26（6）：1239-1241.

DAVID S，HO G，DAY D，et al. Enhanced toxicity with CDK4/6 inhibitors and palliative radiotherapy：non-con- secutive case series and review of the literature[J]. Transl Oncol，2021，14（1）：100939.

GONG J，CHO M，YU K W，et al. A single institution experience with palbociclib toxicity requiring dose modifications[J]. Breast Cancer Res Treat，2018，168（2）：381-387.

OKURA F，SATO Y，MURAKAMI E，et al. A case of interstitial pneumonitis induced by palbociclib[J]. Gan To Kagaku Ryoho，2020，47（6）：997-999.

MATHEW N，JOEL A，ANDREWS A G，et al. CDK4/6 inhibitor induced lung injury：a case report and review of literature[J]. Ecancermedicalscience，2021，15：1245.

LEVY OFER M D，PTASHKIN EKATERINA M D，SHECHTMAN YITZHAK M D，et al. Fatal palbociclib-related interstitial pneumonitis[J]. Arch Clin Med Case Rep，2019，3（4）：162-166.

ALGWAIZ G，BADRAN A A，ELSHENAWY M A，et al. Ribociclib-induced pneumonitis：a case report[J]. Breast Care （Basel），2021，16（3）：307-311.

RAJENDRAN A，KUNOOR A，PUSHPA RAGAHAVAN R，et al. Ribociclib-associated organising pneumonia[J]. BMJ Case Rep，2021，14（12）：e245187.

SADOWSKA A M，SPECENIER P，GERMONPRE P， et al. Antineoplastic therapy-induced pulmonary toxicity[J]. Expert Rev Anticancer Ther，2013，13（8）：997-1006.

RASCHI E，FUSAROLI M，ARDIZZONI A，et al. Cyclin-dependent kinase 4/6 inhibitors and interstitial lung disease in the FDA adverse event reporting system：a pharmacovigilance assessment[J]. Breast Cancer Res Treat，2021，186（1）：219-227.

LEE M Y，YOON S Y，KIM K H，et al. Pulmonary toxicities of molecular targeted antineoplastic agents：a single-center 10-year experience[J]. Korean J Intern Med，2021，36（3）：689-698.

日本乳癌学会. 乳癌診療ガイドライン2018年版[EB/OL]. [2021-11-18]. https：//jbcs.xsrv.jp/guidline/2018/index/yakubutu/y2-cq-15/https://jbcs.xsrv.jp/guidline/2018/index/yakubutu/y2-cq-15/.

FLAHERTY K T，LORUSSO P M，DEMICHELE A， et al. Phase Ⅰ，dose-escalation trial of the oral cyclin-dependent kinase 4/6 inhibitor PD 0332991，administered using a 21-day schedule in patients with advanced cancer[J]. Clin Cancer Res，2012，18（2）：568-576.

SANDBERG L，TAAVOLA H，AOKI Y，et al. Risk factor considerations in statistical signal detection：using subgroup disproportionality to uncover risk groups for adverse drug reactions in VigiBase[J]. Drug Saf，2020，43（10）：999-1009.

KAUFMAN G. Adverse drug reactions：classification，susceptibility and reporting[J]. Nurs Stand，2016，30（50）：53-63.

CONTE P，ASCIERTO P A，PATELLI G，et al. Drug-induced interstitial lung disease during cancer therapies：expert opinion on diagnosis and treatment[J]. ESMO Open，2022，7（2）：100404.

CARR D F，PIRMOHAMED M. Biomarkers of adverse drug reactions[J]. Exp Biol Med （Maywood），2018，243（3）：291-299.

AGUIRRE C，GARCÍA M. Causality assessment in reports on adverse drug reactions. Algorithm of Spanish pharmacovigilance system[J]. Med Clínica Engl Ed，2016，147（10）：461-464.

国家肿瘤质控中心乳腺癌专家委员会，中国抗癌协会肿瘤药物临床研究专业委员会. CDK4/6抑制剂治疗激素受体阳性人表皮生长因子受体2阴性晚期乳腺癌的临床应用共识[J]. 中华肿瘤杂志，2021，43（4）：405-413.

OMARINI C，THANOPOULOU E，JOHNSTON S R. Pneumonitis and pulmonary fibrosis associated with breast cancer treatments[J]. Breast Cancer Res Treat，2014，146（2）：245-258.

SURESH K，NAIDOO J，LIN C T，et al. Immune checkpoint immunotherapy for non-small cell lung cancer： benefits and pulmonary toxicities[J]. Chest，2018，154（6）：1416-1423.

PUZANOV I，DIAB A，ABDALLAH K，et al. Managing toxicities associated with immune checkpoint inhibitors：consensus recommendations from the Society for Immunotherapy of Cancer （SITC） Toxicity Management Wor- king Group[J]. J Immunother Cancer，2017，5（1）：95.

CORNEJO C M，HAUN P，3rdENGLISH J，et al. Immune checkpoint inhibitors and the development of granulomatous reactions[J]. J Am Acad Dermatol，2019，81（5）：1165-1175.

浏览量

下载量

CSCD

文章被引用时，请邮件提醒。

提交

工具集

关联资源

肝癌合并HBV感染患者使用富马酸替诺福韦二吡呋酯致肾损伤1例并文献分析

临床药师参与1例左氧氟沙星致超敏反应的药学监护及文献分析

地舒单抗相关非典型骨折的文献分析

度普利尤单抗致眼部相关不良反应文献分析

舒尼替尼致肾病综合征文献分析